{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:53:07Z","timestamp":1790819587977,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Autoimmune hepatitis (AIH) has occasionally been reported after administration of Coronavirus Disease 2019 (COVID-19) vaccine. The present study aimed to investigate the reported rate and disproportionality of AIH following COVID-19 vaccination.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The Centers for Disease Control (CDC) COVID Data Tracker and the Vaccines Adverse Event Reporting System (VAERS) were queried between 11 December 2020 and 15 March 2022. Reported rates were calculated by cases of AIH divided by the number of vaccinated people. Disproportionate pattern of AIH for COVID-19 vaccination was accessed based on the reporting odds ratio and empirical bayes geometric mean (ROR and EBGM, respectively).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 53 reports of AIH were identified after administration of COVID-19 vaccine during the study period. The overall reported rate of COVID-19 vaccination-related AIH was 0.21 (95% CI 0.16-0.27) per million people. The results found no disproportionate reporting of AIH following COVID-19 vaccination in the VAERS (overall: ROR 1.43, 95% CI 0.52\u20133.96; EBGM05 0.37. mRNA: ROR 1.42, 95% CI 0.51\u20133.94; EBGM05 0.37. Virus vector: ROR 1.57, 95% CI 0.42\u20135.85; EBGM05 0.34).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    COVID-19 vaccine did not increase the risk of AIH. The number of AIH cases reported to VAERS does not suggest a safety concern attributable to COVID-19 vaccine at this time.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1100617","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T03:47:01Z","timestamp":1681444021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Congqin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/s0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3748\/wjg.v13.i15.2238","article-title":"Hepatitis A vaccine associated with autoimmune hepatitis","volume":"13","author":"Berry","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jhep.2022.03.040","article-title":"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis","volume":"77","author":"Boettler","year":"2022","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bcp.13841","article-title":"Safety profile of human papilloma virus vaccines: An analysis of the US vaccine adverse event reporting system from 2007 to 2017","volume":"85","author":"Bonaldo","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2021.04.003","article-title":"Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?","volume":"75","author":"Bril","year":"2021","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100140","DOI":"10.1016\/j.jtauto.2022.100140","article-title":"COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature","volume":"5","author":"Camacho-Dominguez","year":"2022","journal-title":"J. Transl. Autoimmun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"938322","DOI":"10.3389\/fimmu.2022.938322","article-title":"Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1007\/s10620-022-07504-w","article-title":"Autoimmune hepatitis-like syndrome following COVID-19 vaccination: A systematic review of the literature","volume":"67","author":"Chow","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.jaut.2021.102741","article-title":"Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence","volume":"125","author":"Garrido","year":"2021","journal-title":"J. Autoimmun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gronbaek","year":"2014","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: A website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/jcpt.12748","article-title":"Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach","volume":"44","author":"Hosohata","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00002018-200629050-00002","article-title":"Data mining in the US using the vaccine adverse event reporting system","volume":"29","author":"Iskander","year":"2006","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40261-020-00952-0","article-title":"Facial paralysis following influenza vaccination: A disproportionality analysis using the vaccine adverse event reporting system database","volume":"40","author":"Kamath","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3346\/jkms.2022.37.e116","article-title":"Autoimmune hepatitis following vaccination for SARS-CoV-2 in korea: Coincidence or autoimmunity?","volume":"37","author":"Kang","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.26355\/eurrev_202002_20378","article-title":"COVID-19 (Novel Coronavirus 2019) - recent trends","volume":"24","author":"Kannan","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"670370","DOI":"10.3389\/fmed.2021.670370","article-title":"Mortality rate and characteristics of deaths following COVID-19 vaccination","volume":"8","author":"Lv","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jhep.2021.06.044","article-title":"The mRNA COVID-19 vaccine - a rare trigger of autoimmune hepatitis?","volume":"75","author":"McShane","year":"2021","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40264-018-0652-4","article-title":"Central demyelinating diseases after vaccination against hepatitis B virus: A disproportionality analysis within the VAERS database","volume":"41","author":"Mouchet","year":"2018","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.clinre.2019.02.007","article-title":"Development of autoimmune hepatitis after influenza vaccination; trigger or killer?","volume":"43","author":"Muratori","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/picr.PICR_140_18","article-title":"Postlicensure surveillance of human papillomavirus vaccine using the vaccine adverse event reporting system, 2006-2017","volume":"11","author":"Neha","year":"2020","journal-title":"Perspect. Clin. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: A disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0029-1233537","article-title":"Vaccination as a triggering event for autoimmune hepatitis","volume":"29","author":"Perumalswami","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/acs.molpharmaceut.0c00608","article-title":"COVID-19 transmission, current treatment, and future therapeutic strategies","volume":"18","author":"Salian","year":"2021","journal-title":"Mol. Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e11621","DOI":"10.1097\/MD.0000000000011621","article-title":"Autoimmune hepatitis following influenza virus vaccination: Two case reports","volume":"97","author":"Sasaki","year":"2018","journal-title":"Med. Baltim."},{"key":"B31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial nerve palsy following the administration of COVID-19 mRNA vaccines: Analysis of a self-reporting database","volume":"111","author":"Sato","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1080\/14740338.2021.1955101","article-title":"Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines","volume":"20","author":"Sessa","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14760584.2021.1875824","article-title":"COVID-19 vaccine: Where are we now and where should we go?","volume":"20","author":"Soleimanpour","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.vaccine.2020.12.046","article-title":"Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS)","volume":"39","author":"Su","year":"2021","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine - United States, december 14-23, 2020","volume":"70","author":"Team","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/MCG.0000000000001449","article-title":"Epidemiology of autoimmune hepatitis (AIH) in the United States between 2014 and 2019: A population-based national study","volume":"55","author":"Tunio","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/00365521.2016.1224379","article-title":"Vaccine-related autoimmune hepatitis: The same disease as idiopathic autoimmune hepatitis? Two clinical reports and review","volume":"52","author":"van Gemeren","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"102710","DOI":"10.1016\/j.jaut.2021.102710","article-title":"Autoimmune hepatitis triggered by SARS-CoV-2 vaccination","volume":"123","author":"Vuille-Lessard","year":"2021","journal-title":"J. Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"767987","DOI":"10.3389\/fcvm.2022.767987","article-title":"Updated insights on cardiac and vascular risks of proton pump inhibitors: A real-world pharmacovigilance study","volume":"9","author":"Zhai","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jhep.2021.09.031","article-title":"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed","volume":"76","author":"Zin Tun","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1100617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T03:47:04Z","timestamp":1681444024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1100617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":42,"alternative-id":["10.3389\/fphar.2023.1100617"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1100617","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"article-number":"1100617"}}